Core Viewpoint - GLP-1 receptor agonists (GLP-1RA) have gained significant attention due to their broader health benefits beyond diabetes management, including weight loss and metabolic disorder management [6][8]. Group 1: Mechanism and Benefits - GLP-1RA, such as semaglutide and tirzepatide, help regulate blood sugar levels and have a wide distribution of GLP-1 receptors in various organs, enhancing their effectiveness [6][8]. - These medications assist diabetic patients in managing weight, lowering blood pressure, and improving lipid profiles, contributing positively to overall health [8]. Group 2: Oral Administration and Innovation - The development of oral GLP-1RA, particularly semaglutide, faced challenges in preventing degradation by gastric enzymes, which was overcome using the innovative SNAC technology [9]. - SNAC enhances the permeability of semaglutide and protects it from degradation, allowing for effective absorption and rapid entry into the bloodstream [9]. Group 3: Clinical Evidence and Market Impact - Clinical studies have shown that semaglutide can lead to an average weight loss of 12.1% in Chinese adults, significantly outperforming placebo groups [11]. - The approval of semaglutide injection for long-term weight management by the National Medical Products Administration (NMPA) underscores its market value in China [13]. Group 4: Future Guidelines and Recommendations - GLP-1RA's position in treatment guidelines is rising, with recommendations for early use in certain diabetic patients, particularly those with cardiovascular risks [13]. - As an oral formulation, semaglutide is expected to gain further recognition in future guidelines, benefiting Chinese patients with more evidence-based support [14].